Section Arrow
TVTX.NASDAQ
- Travere Therapeutics
Quotes are at least 15-min delayed:2026/08/04 16:34 EDT
After Hours
Last
 62.75
+6.73 (+12.01%)
Bid
61.14
Ask
62.75
High 65 
Low 56.02 
Volume 92.14K 
Regular Hours (Closed)
Last
 56.02
+1.04 (+1.89%)
Day High 
56.67 
Prev. Close
54.98 
1-M High
60 
Volume 
2.45M 
Bid
61.14
Ask
62.75
Day Low
54.22 
Open
54.93 
1-M Low
53 
Market Cap 
5.11B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 56.32 
20-SMA 56.6 
50-SMA 53.31 
52-W High 60.1 
52-W Low 16.96 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.22/1.09
Enterprise Value
5.44B
Balance Sheet
Book Value Per Share
1.06
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
490.73M
Operating Revenue Per Share
2.50
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.3842+0.1041+37.17%-- 
After Hours 0.368 -0.0162 -4.22%
VTGNVistagen Therapeutics, Inc.0.3+0.055+22.45%-- 
After Hours 0.2925 -0.0075 -2.50%
RXRXRecursion Pharmaceuticals3.31+0.13+4.09%-- 
After Hours 3.31 0 0.00%
IBRXImmunityBio6.95-0.2-2.80%-- 
After Hours 6.94 -0.01 -0.14%
GOSSGossamer Bio0.1815+0.0079+4.55%-- 
After Hours 0.1791 -0.0024 -1.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.